AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi
AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi
Read moreMon, 04th May 2020 14:26
AIM WINNERS & LOSERS: AdvancedAdvT buys into M&C Saatchi
Read moreValiRx enters agreement and potential sub-license with TheoremRx
Read moreTRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence
Read more(Sharecast News) - Cancer therapeutics developer ValiRx announced on Monday that it has amended and restated the licence for the VAL201 peptide held by the company from Cancer Research Technology (CRT) to enable a range of sub-licensing options.
Read moreTRADING UPDATES: Custodian sells car showroom; Samarkand buys Napiers
Read moreAIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
Read moreIN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment
Read moreEARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips
Read more(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.
Read moreTRADING UPDATES: Brave Bison, Strix Group see strong performances
Read more(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.
Read moreUK shareholder meetings calendar - next 7 days
Read moreEXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo
Read moreTRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost
Read more(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.
Read more